42.32 USD
▲-1.73+1.27%
盘后 41.69 -0.25%
2026-08-03
市值
$5.62B
市盈率
—
EPS
-2.49
股息率
—
52 周区间
8.59 – 49.20
成交量
1.86M
Beta
2.21
目标价
60.00
52W 低 8.5952W 高 49.20
价格走势
公司简介
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi...